Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results
03 mai 2018 16h01 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported...
Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
16 avr. 2018 07h00 HE
|
Apricus Biosciences, Inc.
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus...
Apricus Biosciences Announces Closing of $3.55 Million Public Offering
04 avr. 2018 16h01 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
28 mars 2018 08h00 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it...
Apricus Biosciences Announces Proposed Public Offering
27 mars 2018 16h33 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it...
Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA
26 mars 2018 07h00 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
01 mars 2018 16h01 HE
|
Apricus Biosciences, Inc.
Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call /...
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
21 févr. 2018 07h00 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
16 févr. 2018 07h00 HE
|
Apricus Biosciences, Inc.
SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
02 nov. 2017 16h01 HE
|
Apricus Biosciences, Inc.
Vitaros U.S. NDA Resubmission Review Remains on TrackPDUFA Goal Date of February 17, 2018 Conference Call / Webcast Today, November 2, 2017 at 4:30 p.m. ET SAN DIEGO, Calif., Nov. 02, 2017 (GLOBE...